News

Pharmacy of the World: India’s Generic Medicine Revolution

India is the world’s largest exporter of generic medicines, contributing significantly to global healthcare. The country accounts for 20% of the world’s generic drug supply and 60% of the global vaccine supply.

• By Pooja Chaturvedi Sah
• New Delhi
• Jun 20, 2024

News

India’s pharmaceutical industry, renowned for being the largest exporter of generic medicines, is undergoing a transformative shift aimed at increasing accessibility and affordability of essential drugs. 

The All India Drug Action Network (AIDAN), a coalition of health organizations advocating rational drug policies for over four decades, has recently urged the health ministry to support a proposal allowing government-run generic medicine centers, known as Jan Aushadhi Kendras, to dispense generic substitutes for prescription medications. 

This move has the potential to significantly impact the availability of essential drugs like anti-cancer and tuberculosis medications. 

Pushing for Policy Change: AIDAN’s Advocacy for Generic Substitutions 

In a letter dated June 11, AIDAN called for amendments to Schedule ‘H’ under the Drugs and Cosmetics Act, 1940. The proposed changes would empower Jan Aushadhi Kendras to dispense generic substitutes for branded prescription medications. AIDAN also recommended the formation of an expert panel to assess the feasibility of this initiative, as per the Central Drugs Standard Control Organisation (CDSCO) Technical Advisory Board’s recommendations. 

Opposition and Support 

While the Indian Pharmaceutical Alliance (IPA) has opposed the proposal, citing potential demands for similar substitutions from other pharmacy channels that they argue might not benefit patients, health experts have refuted this claim. They believe that allowing generic substitutions at Jan Aushadhi Kendras will prove to millions that generics are just as effective as their branded counterparts. 

Government Directives and Regulations 

Clause 1.5 of the Indian Medical Council (Professional Conduct, Etiquette, and Ethics) Regulations, 2002, mandates that physicians prescribe drugs with generic names legibly. Additionally, directives from the Directorate General of Health Services require all Central Government hospitals to prescribe generic medicines only, extending this practice to CGHS doctors and wellness centers.

In a push towards broader adoption, the Union Health Ministry has also urged private hospital doctors to prescribe generics, starting with Central Government Health Scheme (CGHS) beneficiaries. 

The Role and Impact of Jan Aushadhi Kendras: Affordable Medicine for All 

One of India's major national and local push for the affordable generic medicines started with the Jan Aushadhi initiative. The Jan Aushadhi initiative, launched in 2008 and later rebranded under the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP), aims to provide quality medicines at affordable prices through dedicated outlets. The initiative has grown to include around 9,512 stores as of June 2023, offering medicines at 50-90% lower prices compared to branded drugs in the open market. 

Ensuring Quality and Efficacy 

According to the Ministry of Health and Family Welfare, quality assurance for the generics is given a critical weightage under the  PMBJP. The Pharmaceuticals & Medical Devices Bureau of India (PMBI) procures medicines only from WHO-GMP certified suppliers. Each batch undergoes rigorous testing in NABL-accredited laboratories before being dispatched to Jan Aushadhi Kendras. Additionally, regulatory measures from the Ministry and CDSCO ensure that generic medicines meet the required efficacy and safety standards. 

India: The Pharmacy of the World 

Leading Exporter 

India is the world’s largest exporter of generic medicines, contributing significantly to global healthcare. The country accounts for 20% of the world’s generic drug supply and 60% of the global vaccine supply. Indian pharmaceutical companies play a critical role in the US market, supplying 47% of all generic prescriptions in 2022, leading to substantial savings for the US healthcare system. 

International Collaborations 

Indian generics are also crucial for reducing healthcare costs in Latin America, with Indian companies establishing manufacturing plants in Brazil, Mexico, and Argentina. The Jan Aushadhi scheme’s success has attracted interest from other countries, with Mauritius adopting the initiative and Nepal seeking to establish similar centers. 

Impact on Global Healthcare 

Medicines from Indian companies provided $219 billion in savings to the US healthcare system in 2022 alone, and a total of $1.3 trillion in savings between 2013 and 2022. Generics from Indian companies are expected to generate an additional $1.3 trillion in savings over the next five years.

Western NGOs and foundations also buy generic medicines from India, contributing to the reduction of healthcare costs worldwide.

A global stand for Make-in-India Pharma: India’s Rejection of the European Free Trade Agreement (FTA)

Recently, India rejected the demand for ‘data exclusivity’ with the European Free Trade Association (EFTA) towards a free trade agreement. Iceland, Liechtenstein, Norway, and Switzerland constitute the European Free Trade Association (EFTA). 

India’s negotiation was marked by its firm stance on protecting public health and ensuring access to affordable medicines. The primary contention revolves around the demands from the EFTA for India to adopt TRIPS-plus provisions, including data exclusivity and patent linkage. 

Data exclusivity would prevent generic manufacturers from using clinical trial data submitted by original drug developers to regulatory agencies for a certain period, effectively extending the monopoly period of patented drugs. Patent linkage would delay the approval of generic drugs until the expiration of patents on the original drugs, further hindering the availability of affordable generics. 

India has consistently rejected these provisions, arguing that they would undermine its ability to produce and export generic medicines, which are crucial for public health not only in India but globally. This stance aligns with India’s commitment to providing affordable healthcare and ensuring the accessibility of essential medicines, especially for low and middle-income countries. 

According to the think tank Global Trade Research Initiative (GTRI), India, by opposing demands of developed nations on issues like 'data exclusivity' and 'patent linkage' in free trade agreements (FTAs), has ensured that there would be greater market access for the generic drug manufacturers and cost of life-saving medicines will be reduced significantly.

The report also stated that this stance aligns with the country’s developmental goals, and prevent the establishment of unfair monopolies, especially in the pharmaceutical sector. India’s approach, according to the report, also reflects a broader effort to protect traditional knowledge and ensure the availability of affordable medicines which is critical to address global healthcare challenges. 

History of India’s Pharmaceutical Industry: Early Beginnings and Foreign Domination

However, historically, India’s pharmaceutical sector was dominated by foreign companies, primarily American and European firms, which controlled nearly 90% of the market. The 1960s marked the beginning of a significant shift as the Indian government initiated efforts to promote domestic companies, leading to substantial success in the 1970s. 

Patent Act of 1970: A Turning Point 

A crucial turning point came with the enactment of the Patent Act of 1970, which prohibited the patenting of medical products in the country. This landmark decision paved the way for substantial advancements, enabling Indian companies to engage in reverse engineering. This practice accelerated the mass production of drugs, allowing Indian companies to replicate existing drugs and meet a staggering 95% of the domestic drug market’s demands by 2006. 

Growth of Domestic Firms 

Through meticulous analysis of existing drugs, Indian companies were able to replicate them efficiently. For example, Ibuprofen’s introduction in 1967 was swiftly followed by the introduction of its Indian generic counterpart in 1973. Similarly, Ciprofloxacin’s global debut was closely followed by the introduction of its Indian version within just three years. This drive led to a significant increase in the number of domestic pharmaceutical firms. 

Challenges and Roadmap Ahead 

Despite its successes, the Indian pharmaceutical industry faces several challenges:

• Quality Concerns: The Indian Medical Association (IMA) has raised concerns about the quality of generic medicines, pointing out that less than 0.1% of drugs manufactured in India are tested for quality. The IMA advocates for a “one drug, one quality, one price” system to ensure uniformity in drug pricing and quality. 
• Regulatory and Production Challenges: India’s dependency on China for 80% of its active pharmaceutical ingredients (APIs) poses risks of price volatility and supply disruptions. Regulatory frameworks need continuous refinement to balance the production of generics with the investment in research and development. Harmonization of domestic and international regulations is essential for streamlining processes and ensuring global compliance. 
• Counterfeit Drug Production: India faces increased scrutiny from organizations like WHO over the production of substandard and counterfeit drugs. Reports suggest that fake drugs constitute 25% of India’s domestic medicine market, with WHO estimating that 35% of the world’s counterfeit drugs are produced in India. This is a significant challenge for the industry, affecting its credibility and reputation. 
• Incidents and Safety Concerns: The recent incident in the Gambia, where children suffered acute kidney injuries after consuming contaminated syrup from an Indian manufacturer, highlights the need for stricter quality control and regulatory oversight. Ensuring that such incidents do not recur is crucial for maintaining global trust in Indian pharmaceuticals. 
• Intellectual Property Rights (IPRs): India has faced pressure from developed countries to adopt TRIPS-plus provisions, such as data exclusivity and patent linkage, in free trade agreements. These provisions could hinder the production of affordable generics and extend monopolies on patented drugs.

Future Prospects and Solutions 

Addressing these challenges requires a multi-faceted approach:

• Strengthening Quality Assurance: Improving the quality assurance processes for generic medicines is paramount. This includes increasing the percentage of drugs tested for quality and ensuring that manufacturing standards are uniformly high across the industry. Strengthening regulatory frameworks and increasing the frequency of inspections can help address quality concerns. 
• Investing in R&D: Sustained investment in research and development is essential for the growth of the pharmaceutical industry. This includes providing incentives for innovation and supporting the development of new drug formulations. The government’s Production Linked Incentive (PLI) scheme, introduced in 2021, is a step in the right direction, offering Rs. 15,000 crores to boost domestic production and innovation. 
• Reducing Dependency on Imports: Reducing dependency on imports, particularly from China, is crucial for the stability of the Indian pharmaceutical industry. Developing domestic sources of APIs and fostering collaborations between manufacturers can help mitigate the risks associated with supply disruptions and price volatility. 
• Addressing Counterfeit Drugs: Combating the production and distribution of counterfeit drugs requires a multi-faceted approach. This includes stricter penalties for offenders, better tracking and tracing of pharmaceutical products, and increased public awareness about the dangers of counterfeit drugs. International collaborations can also help in addressing this global issue. 
• Balancing Affordable Access with IP Rights: Striking a balance between ensuring affordable access to medicines and protecting intellectual property rights is essential. India’s stance on rejecting data exclusivity and other TRIPs-plus provisions in trade agreements reflects its commitment to this balance. Ongoing discussions with stakeholders can help refine this approach and address the concerns of all parties involved. 
• Leveraging Digital Technologies: The integration of digital technologies in the pharmaceutical industry can enhance efficiency, improve supply chain management, and ensure better compliance with regulatory standards. Digital tools can also facilitate more effective quality control and monitoring of drug production processes. 

In conclusion, India’s journey in the pharmaceutical realm is one of transformation and progress. The push for wider adoption of generic medicines through initiatives like Jan Aushadhi Kendras reflects a commitment to making healthcare affordable and accessible to all. 

Balancing affordability with quality, ensuring stringent oversight, and fostering innovation are key to sustaining this progress. 

As India continues to play a pivotal role in global healthcare, the collaborative efforts of all stakeholders will be crucial in shaping a healthier, brighter future.